FDA Moves to Ban Compounded GLP-1 Drugs Semaglutide and Tirzepatide

The FDA has announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — a regulatory move that would prohibit outsourcing facilities from legally compounding these drugs from bulk substances. This decision has major implications for the millions of Americans who have turned to compounded GLP-1 receptor agonists as lower-cost alternatives to brand-name drugs like Ozempic, Wegovy, Mounjaro, and Victoza.

Under Section 503B of the Federal Food, Drug, and Cosmetic Act, outsourcing facilities can only compound drugs from bulk substances if those substances appear on the 503B bulks list or if the drug is on the FDA's official shortage list. With GLP-1 drugs no longer listed as in shortage, the FDA reviewed nominations to keep them on the bulks list and concluded there was insufficient evidence of clinical need to justify continued bulk compounding.

The practical impact is significant. Compounded versions of these drugs have been widely used by weight-loss clinics and telehealth platforms, often at a fraction of the cost of brand-name products. Patients using compounded semaglutide or tirzepatide for obesity, metabolic syndrome, or type 2 diabetes management may face sharply higher costs or loss of access if this proposal is finalized.

FDA Commissioner Marty Makary emphasized that when approved drugs are available, compounding from bulk substances requires a clear clinical justification under the law. The agency is inviting public comments through June 29, 2026, before issuing a final determination, leaving a window for patient advocates and clinicians to weigh in.

For health-conscious individuals using or considering GLP-1 therapies for longevity-adjacent goals like metabolic optimization or weight management, this regulatory shift underscores the importance of monitoring policy developments. Access to and affordability of these drugs may change substantially depending on the final ruling.